Evidence mapPaperPMID 40103309Full record

ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2025

Rising pressure to understand the risks of hypertension in children with narcolepsy type 1.

Elizabeth Montesano, Maria E Garcia, Shannon Lyon, Jennifer Worhach, Grace Wang, Bo Zhang, Joshua August, Kiran Maski

Abstract read
In one paragraph

Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. When a trail leads to a highway: enhancing the understanding of hypertension in pediatric type 1 narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elizabeth MontesanoDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Maria E GarciaSchool of Medicine, Ponce Health Science University, Ponce, Puerto Rico.
Shannon LyonDepartment of Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Jennifer WorhachDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Grace WangDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Bo ZhangDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.
Joshua AugustDepartment of Neurology, Boston Medical Center, Boston, Massachusetts.
Kiran MaskiDepartment of Neurology, Boston Children's Hospital, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesMost children/adolescents with narcolepsy type 1 (NT1) are treated with stimulants or modafinil, yet the cardiovascular effects of these medications have not been investigated in this population. We compared vital signs in youth with NT1 before and after exposure to stimulants/modafinil to test the hypotheses that these medications increase rates of elevated blood pressure (BP) and hypertension and that body mass index influences these outcomes.

methodsIn this retrospective study, we collected electronic medical data including vital signs and polysomnography/Multiple Sleep Latency Test results from 39 youth with NT1 aged 7-18 at 3 points over a 20-month period: baseline (drug-naïve/weaned), after initiating treatment, and after treatment optimization. We performed stepwise regression to determine predictors of baseline elevated BP/hypertension. We used McNemar's test and generalized estimating equations to assess the effects of stimulant/modafinil exposure on vital signs.

resultsThe prevalence of elevated BP/hypertension at baseline was 51% in our cohort and increased 21% from baseline to the final visit (

conclusionsYouth with NT1 are at risk for elevated BP/hypertension, particularly after stimulant/modafinil treatment. We recommend revising clinical guidelines to address this risk and advocate for controlled studies to better understand the cardiovascular risks and implications of these treatments in pediatric NT1. CITATION: Montesano E, Garcia ME, Lyon S, et al. Rising pressure to understand the risks of hypertension in children with narcolepsy type 1.

Indexed as

Central Nervous System StimulantsHypertensionModafinilNarcolepsyAdolescentBlood PressureBody Mass IndexChildFemaleHumansMalePolysomnographyRetrospective StudiesRisk FactorsCentral Nervous System StimulantsModafinilblood pressurehypertensionnarcolepsyobesitypediatricsleepweight

Identifiers

PMID40103309
PMCPMC12134576

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.